Aquestive Therapeutics (AQST) Assets Average (2018 - 2026)

Aquestive Therapeutics' Assets Average history runs 9 years deep, the most recent figure standing at $150.8 million for Q1 2026.

• In Q1 2026, Assets Average rose 48.07% year-over-year to $150.8 million; the TTM figure through Mar 2026 stood at $150.8 million (up 48.07% YoY), while the FY2025 annual figure was $130.9 million, up 64.85% from the prior year.
• Assets Average was $150.8 million for Q1 2026 at Aquestive Therapeutics, down from $162.0 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $162.0 million in Q4 2025 to a low of $54.1 million in Q3 2022.
• Historically, Assets Average has averaged $90.4 million across 5 years, with a median of $93.5 million in 2024.
• The sharpest annual moves came in 2024 and 2025: Assets Average jumped 108.94% in 2024, then retreated 20.72% in 2025.
• A 5-year view of Assets Average shows it stood at $54.5 million in 2022, then climbed by 7.3% to $58.4 million in 2023, then surged by 80.88% to $105.7 million in 2024, then surged by 53.27% to $162.0 million in 2025, then decreased by 6.92% to $150.8 million in 2026.
• The last three Assets Average figures came in at $150.8 million (Q1 2026), $162.0 million (Q4 2025), and $128.6 million (Q3 2025), per Business Quant data.